
T-Therapeutics: A $133 million Series B to bring next-generation immunotherapies closer to clinical application
The development of new cancer treatments increasingly depends on the ability to identify and target biological mechanisms that conventional therapies cannot effectively reach. T-Therapeutics, a Cambridge-based biotechnology company, is working on precisely this challenge by developing next-generation T-cell receptor (TCR) T-cell engager therapies for cancer and autoimmune diseases. The company’s approach combines advances in immunology,




